Clinical reviewer: Dr. Sarah Boss, MD

COGNIFUL, part of THE BALANCE GROUP, publishes this guide. We compare selected medical and addiction providers with our possible residential role at a later or clinically appropriate stage. This is a publisher’s comparison, not an independent ranking. A hospital, outpatient prescriber and private residence may support different parts of one care plan.

Physical dependence means the body has adapted to a medicine and withdrawal can occur when treatment changes. It can develop during prescribed benzodiazepine use without a substance use disorder. The joint clinical guideline explicitly distinguishes those situations. An assessment should therefore do more than apply an addiction label because someone has taken a medicine regularly or experienced difficulty reducing it. [1]

A substance use disorder involves a different clinical assessment of the pattern of use and its consequences. Dependence and a use disorder can coexist, but the treatment conversation should explain what has actually been identified. Someone with prescribed dependence may need ongoing medical care for anxiety, sleep or another original indication as well as a medication review.

Ask the professional to describe the proposed goal. It may involve reviewing risks and benefits, planning an appropriate change, treating harmful use or improving support for the original condition. The individual should understand why a recommendation fits their history. A detox package is not a substitute for that reasoning, and a residential admission is not automatically necessary.

The table includes providers that publish medical or addiction services and a residence with a different scope. Confirm the exact benzodiazepine pathway at the accepting campus. A broad detox service listing does not establish experience with every medication history, previous withdrawal difficulty or co-occurring illness. Ask which professional will make the assessment before a program is offered.

For an international inquiry, verify the actual location of each stage. A provider may offer assessment, hospital treatment and outpatient follow-up through different units. The person needs to know where they will be, which team is responsible and who accepts the next step. Shared branding between services does not by itself complete a clinical handover.

The joint guideline recognizes that many people can be managed in outpatient care, while some need inpatient treatment because of significant risks, unstable medical or psychiatric conditions, or the potential for severe withdrawal. Ask the clinician to explain the factors that support the recommendation. The most intensive setting is not automatically the most appropriate, and the most comfortable setting is not necessarily medically sufficient. [1]

The assessment should include the actual medicine, pattern of use, duration, other prescriptions, alcohol or other substances, previous withdrawal and relevant health history. Previous seizures, severe withdrawal or serious psychiatric events need explicit discussion. The person should not omit difficult information in an effort to qualify for a preferred residence or a particular travel date.

Ask how the provider responds if new information changes the recommended care level. A sound admission process may remain conditional until records or additional medical review are available. Explaining those limits is more useful than guaranteeing suitability from a brief inquiry. The person should understand what is confirmed and what still requires assessment.

The FDA warns that abruptly stopping or rapidly reducing benzodiazepines can cause serious withdrawal, including seizures. Dependence may occur even when the medicine was taken as prescribed. The care plan should be clinician-led and individualized. Do not independently stop, reduce or substitute medication to prepare for a consultation, an admission or an international flight. [7]

The joint guideline describes medication changes that may take a prolonged period for some people. A short admission can therefore be one part of a longer process rather than a promise of completion. Ask what a provider means by detox, which medical decisions occur during the stay and what follow-up is available if the plan continues afterward. [1]

An advertised duration should not determine the pace of treatment. Ask what happens if the person needs more review, a different setting or a revised plan. The answer should identify clinical responsibility and practical arrangements rather than suggest that difficulty means the client failed a standard schedule. This guide does not provide a medication schedule or a basis for changing treatment independently.

During a medication review, withdrawal-related symptoms, a return of the original condition and other health problems may need to be distinguished. The guideline discusses the challenge of making those judgments and the importance of ongoing assessment. A person should be able to report physical and psychological symptoms without having them dismissed as simply anxiety or automatically attributed to withdrawal. [1]

Ask who evaluates changing symptoms and how the person can communicate between scheduled appointments. A symptom report should lead to an appropriate clinical decision, not a demand to interpret the problem alone. The program should also explain the limits of remote contact and what requires local medical assessment, particularly when treatment involves several countries.

Some people experience prolonged difficulties, but an individual course cannot be predicted from a generic description. The useful question is how the provider offers review and support if progress is less straightforward than expected. Avoid treating either a promise of quick resolution or a prediction of inevitable prolonged illness as an adequate individual assessment. [1]

If benzodiazepines were prescribed for anxiety, insomnia or another condition, ask what care will address that need during the medical process. The joint guideline supports treating co-occurring conditions rather than focusing only on medication reduction. The plan should identify the relevant professional, the proposed therapeutic work and how clinical decisions are coordinated. [1]

For chronic insomnia, the National Heart, Lung, and Blood Institute identifies cognitive behavioral therapy for insomnia as a usual first treatment option. This is a reason to ask about appropriate sleep assessment and access to evidence-based care. It does not establish that every detox program, or COGNIFUL, provides a dedicated sleep service or a particular therapy. [8]

When the original indication is unclear or several prescribers have been involved, ask how the history will be reconstructed. A person should not have to prove that their symptoms are real before those symptoms are considered. The medical and therapeutic goals should be understandable together, with neither the underlying condition nor medication-related concerns excluded from discussion.

The FDA warns of serious risks when benzodiazepines are combined with opioids, alcohol or other substances. Tell the assessing team about actual use, including medicines from different prescribers and substances used only occasionally. Uncertain information should be identified as uncertain. The provider needs a complete picture before recommending a setting or a medication plan. [7]

If opioid use disorder is also present, the plan must account for appropriate ongoing treatment. The CDC recommends medication treatment and advises against detoxification alone for opioid use disorder. Ask which clinician coordinates those needs with the benzodiazepine plan, so one admission does not inadvertently leave another essential treatment unresolved. [9]

Suspected overdose, breathing difficulty, a seizure, severe confusion or immediate danger requires urgent local medical help. A residential admissions team or a planned flight should not delay that response. Decisions about longer-term care can follow assessment and stabilization in the appropriate setting. [7]

Ask who has prescribing responsibility during the proposed program, which professionals monitor the person and what care is available when symptoms change. Distinguish onsite services from external appointments or referral agreements. A physician’s association with a provider does not by itself establish continuous presence or hospital-level capability.

The proposal should also explain what the service cannot manage. If it requires a different provider for acute symptoms, specialist review or a longer medical process, ask how that transfer occurs. Knowing a program’s limits helps a person assess fit. A broad statement that care is personalized does not replace an operational plan for the actual medical needs.

For outpatient care, ask about agreed reviews and the route for contacting the responsible professional. For an inpatient admission, ask what makes discharge appropriate and which clinician accepts follow-up. These questions address different settings without assuming that everyone needs a residential program or that outpatient treatment means managing withdrawal alone. [1]

Before comparing countries, identify the professional who can support the person over time. A local prescriber may already know the history and can be central to the return-home plan. If treatment abroad is considered, ask whether the anticipated benefit justifies changing services and whether essential care can remain continuous throughout the journey.

Confirm medication availability and travel requirements with clinicians and the appropriate authorities for the route. A prescription accepted in one country should not be assumed to transfer unchanged elsewhere. The receiving medical service must understand and accept the current plan before the person travels, including any requirements that continue during residential care.

Agree the language, content and secure transfer of records. A useful handover includes the history, current treatment, clinical course and remaining concerns, with the person’s consent. Family members may assist with practical organization, but should not become the only link between clinicians or the people expected to reconcile medical instructions.

COGNIFUL is based in Mallorca, Spain. Its published prescription-medication service and clinical standards require assessment of medical needs, withdrawal risk and suitability for the residence. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. If hospital treatment or another medical service is required first, the sequence should reflect that requirement. [10] [2]

Suitability does not mean that every person must have completed every possible medication change before residential care can be considered. It means the current medical needs, prescribing arrangements and support required must be understood and appropriate for the setting. Ask what can be supported directly, what remains external and whether the relevant professionals have accepted the plan.

For a suitable client, residential work may address coping, the circumstances around harmful use, relationships and preparation for life at home. Where there is prescribed dependence without addiction, the goals should reflect that distinction. The proposal should not impose an addiction narrative that does not fit the assessment or suggest that comfort itself resolves the medical process.

The residence has a maximum of four clients at any time, each with a private suite. Clinical and bodywork sessions are individual. The residence, chef, personal manager, other holistic sessions, excursions and activities are shared. This describes the living arrangement and session format. It does not prove a staffing ratio, continuous medical supervision or a superior outcome. [6]

COGNIFUL Premier and Premier Plus both include assessment, a personal plan and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Base-program follow-up is individually agreed. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. [6] View program fees

A written proposal should confirm duration, inclusions and total cost, including the status of any separately arranged medical treatment. The residence is generally self-pay, without direct insurer billing or guaranteed reimbursement. The price comparison should concern the actual proposed residential work, not imply that the higher-priced program establishes greater detox capability. [6]

Continuing care should identify the clinician who will manage any ongoing medication review, the accepted next appointment and the support COGNIFUL has agreed to provide. Do not assume unrestricted cross-border prescribing or emergency access. The residential phase should connect with a workable local plan rather than leave the person with a discharge document and no receiving service. [11] [2]

Ask how the team will describe progress

A meaningful review should explain what has changed for this person, what still needs attention and why the current care setting remains appropriate. Ask how the team will consider daily functioning, the original symptoms, medical concerns and the individual’s agreed goals. Finishing a booked stay or meeting a predetermined medication milestone is not, by itself, a complete description of recovery.

If a provider quotes results, ask which people were included, what was measured and over what follow-up period. A general satisfaction statement does not establish an outcome for a comparable benzodiazepine history. The most useful discussion connects the provider’s evidence and clinical reasoning to the proposed plan without promising that one person’s course will match someone else’s.

• How does the assessment distinguish dependence from a substance use disorder?
• What specific risks determine outpatient, inpatient or other medical care?
• Who is responsible if symptoms or the proposed medical plan change?
• How are the original condition and other medications addressed?
• Which professional has accepted follow-up after the admission or journey?

Request answers about the actual person rather than a standard package. The most suitable pathway may remain local, involve a medical admission, or include a later residential stay. Its quality depends on clinical reasoning and accepted responsibilities, with privacy and comfort considered within those requirements.

Does physical dependence mean I need addiction rehab?

No. Dependence can occur during prescribed use without a substance use disorder. Assessment should determine the diagnosis and appropriate medical or therapeutic support. [1]

Is a short detox always preferable?

No universal duration is appropriate. The process should be individualized, and some people need prolonged follow-up. Abrupt or rapid changes can be dangerous. [1] [7]

Can benzodiazepine withdrawal be managed as an outpatient?

The guideline recognizes outpatient care for many people. Some need inpatient treatment because of their assessed risks or medical and psychiatric needs. A clinician should determine the setting. [1]

Does COGNIFUL provide onsite benzodiazepine detox?

COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. [2] The medical plan, prescribing responsibilities and any additional specialist support are confirmed individually.

COGNIFUL admissions can explain what information is needed to consider a Mallorca stay. Share the prescribing history, current treatment and responsible clinician’s recommendations. Medical assessment should establish the appropriate sequence before a residential booking or international journey is finalized. [6] [2]

1. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
2. Clinical scope, suitability and care coordination — COGNIFUL.
3. Psychiatry and Clinical Psychology Department — Clínica Universidad de Navarra.
4. Priory Hospital Roehampton — Priory.
5. Addiction and mental health services in Center City — Hazelden Betty Ford Foundation.
6. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
7. Benzodiazepine safety communication — US Food and Drug Administration.
8. Insomnia treatment — National Heart, Lung, and Blood Institute.
9. Opioid use disorder: treating — Centers for Disease Control and Prevention.
10. Prescription medication concerns and residential treatment — COGNIFUL.
11. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.